Mechanisms of infection by the human fungal pathogen Cryptococcus neoformans

Future Microbiology

Volumn 7, Issue 11, 2012, Pages 1297-1313

  Sabiiti, Wilber ^a   May, Robin C ^b  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

blood brain barrier; brain; cryptococcal meningoencephalitis; Cryptococcus neoformans; dissemination; infection; macrophages

Indexed keywords

MELANIN; PHOSPHOLIPASE; PROTEINASE; UREASE;

BRAIN; CELL PHAGOCYTOSIS; CRYPTOCOCCAL MENINGITIS; CRYPTOCOCCAL MENINGOENCEPHALITIS; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; FUNGAL COLONIZATION; FUNGAL METABOLISM; FUNGUS TRANSMISSION; HOST CELL; HUMAN; IMMUNOMODULATION; LUNG ALVEOLUS CELL; LUNG INFECTION; MENINGOENCEPHALITIS; NONHUMAN; NUTRIENT SUPPLY; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SURVIVAL; SYSTEMIC MYCOSIS; TRANSCELLULAR CELL MIGRATION;

BLOOD-BRAIN BARRIER; CRYPTOCOCCUS NEOFORMANS; HUMANS; LUNG DISEASES, FUNGAL; MENINGITIS, CRYPTOCOCCAL; SPORES, FUNGAL;

EID: 84867719522     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.12.102     Document Type: Review

References (177)

1. Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 23(4), 525-530 (2009
2. Meya DB, Manabe YC, Castelnuovo B et al. Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count < or = 100 cells/microL who start HIV therapy in resource-limited settings. Clin. Infect. Dis. 51(4), 448-455 (2010).
3. Kambugu A, Meya DB, Rhein J et al. Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy. Clin. Infect. Dis. 46(11), 1694-1701 (2008).
4. Jarvis JN, Boulle A, Loyse A et al. High ongoing burden of cryptococcal disease in Africa despite antiretroviral roll out. AIDS 23(9), 1182-1183 (2009).
5. Saag MS, Graybill RJ, Larsen RA et al. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin. Infect. Dis. 30(4), 710-718 (2000).
6. Lortholary O. Management of cryptococcal meningitis in AIDS: The need for specific studies in developing countries. Clin. Infect. Dis. 45(1), 81-83 (2007).
7. Byrnes EJ, Heitman J. Cryptococcus gattii outbreak expands into the northwestern United States with fatal consequences. F1000 Biol. Rep. 1, 62 (2009).
8. Chau TT, Mai NH, Phu NH et al. A prospective descriptive study of cryptococcal meningitis in HIV uninfected patients in Vietnam - high prevalence of Cryptococcus neoformans var grubii in the absence of underlying disease. BMC Infect. Dis. 10, 199 (2010).
9. Zhu LP, Wu JQ, Xu B, Ou XT, Zhang QQ, Weng XH. Cryptococcal meningitis in non-HIV-infected patients in a Chinese tertiary care hospital, 1997-2007. Med. Mycol. 48(4), 570-579 (2010).
10. Singh N, Alexander BD, Lortholary O et al. Pulmonary cryptococcosis in solid organ transplant recipients:Clinical relevance of serum cryptococcal antigen. Clin. Infect. Dis. 46(2), e12-e18 (2008).
11. Singh N, Forrest G. AST infectious diseases community of practice:Cryptococcosis in solid organ transplant recipients. Am. J. Transplant. 9(Suppl. 4), S192-S198(2009).
12. McQuiston TJ, Williamson PR. Paradoxical roles of alveolar macrophages in the host response to Cryptococcus neoformans. J. Infect. Chemother. 18(1), 1-9 (2012).
13. Springer DJ, Chaturvedi V. Projecting global occurrence of Cryptococcus gattii. Emerg. Infect. Dis. 16(1), 14-20 (2010).
14. Knoke M, Schwesinger G. One hundred years of cryptococcosis. Medical mycology in the 19th century in Greifswald. Mycoses 37(SUPPL1, S28-S33 (1994).
15. Mitchell TG, Perfect Jr. Cryptococcosis in the era of AIDS - 100 years after the discovery of Cryptococcus neoformans. Clin. Microbiol. Rev. 8(4), 515-548 (1995).
16. Franzot SP, Salkin IF, Casadevall A. Cryptococcus neoformans var. grubii: Separate varietal status for Cryptococcus neoformans serotype A isolates. J. Clin. Microbiol. 37(3), 838-840 (1999).
17. Boekhout T, van Belkum A, Leenders AC et al. Molecular typing of Cryptococcus neoformans: Taxonomic and epidemiological aspects. Int. J. Syst. Bacteriol. 47(2), 432-442 (1997).
18. Kwon-Chung KJ, Boekhout T, Fell JW, Diaz M. Proposal to conserve the name Cryptococcus gattii against C. hondurianus and C. bacillisporus (Basidiomycota, Hymenomycetes, Tremellomycetidae). Taxon 51(4), 804-806 (2002).
19. Franzot SP, Fries BC, Cleare W, Casadevall A. Genetic relationship between Cryptococcus neoformans var. neoformans strains of serotypes A and D. J. Clin. Microbiol. 36(8), 2200-2204 (1998).
20. Ngamskulrungroj P, Gilgado F, Faganello J et al. Genetic diversity of the Cryptococcus species complex suggests that Cryptococcus gattii deserves to have varieties. Plos One 4(6), e5862 (2009).
21. Simwami SP, Khayhan K, Henk DA et al. Low diversity Cryptococcus neoformans variety grubii multilocus sequence types from Thailand are consistent with an ancestral African origin. Plos Pathog. 7(4), e1001343 (2011).
22. Litvintseva AP, Thakur R, Vilgalys R, Mitchell TG. Multilocus sequence typing reveals three genetic subpopulations of Cryptococcus neoformans var. grubii (serotype A), including a unique population in Botswana. Genetics 172(4), 2223-2238 (2006).
23. Heitman J, Kozel TR, Kwon-Chung KJ, Perfect JR, Casadevall A. Cryptococcus: From Human Pathogen to Model Yeast. American Society for Microbiology Press, Washington, DC, USA, 347-349 (2010).
24. Litvintseva AP, Carbone I, Rossouw J, Thakur R, Govender NP, Mitchell TG. Evidence that the human pathogenic fungus Cryptococcus neoformans var. grubii may have evolved in Africa. Plos One 6(5), e19688 (2011).
25. Litvintseva AP, Lin X, Templeton I, Heitman J, Mitchell TG. Many globally isolated AD hybrid strains of Cryptococcus neoformans originated in Africa. Plos Pathog. 3(8), e114 (2007).
26. Casadevall A, Perfect JR. Cryptococcus neoformans. American Society for Microbiology Press, WA, USA (1998).
27. Molez JF. The historical question of acquired immunodeficiency syndrome in the 1960s in the Congo River basin area in relation to cryptococcal meningitis. Am. J. Trop. Med. Hyg. 58(3), 273-276 (1998).
28. Casadevall A, Cassone A, Bistoni F et al. Antibody and/or cell-mediated immunity, protective mechanisms in fungal disease: An ongoing dilemma or an unnecessary dispute? Med. Mycol. 36(SUPPL1, S95-S105 (1998).
29. Lin X, Patel S, Litvintseva AP, Floyd A, Mitchell TG, Heitman J. Diploids in the Cryptococcus neoformans serotype A population homozygous for the a mating type originate via unisexual mating. Plos Pathog. 5(1), e1000283 (2009).
30. Severo CB, Xavier MO, Gazzoni AF, Severo LC. Cryptococcosis in children. Paediatr. Respir. Rev. 10(4), 166-171 (2009).
31. Hernandez AD. Cutaneous cryptococcosis. Dermatol. Clin. 7(2), 269-274 (1989).
32. Liu PY, Yang Y, Shi ZY. Cryptococcal liver abscess: A case report of successful treatment with amphotericin-B and literature review. Jpn J. Infect. Dis. 62(1), 59-60 (2009).
33. Wu B, Liu H, Huang J, Zhang W, Zhang T. Pulmonary cryptococcosis in non-AIDS patients. Clin. Invest. Med. 32(1), E70-E77 (2009).
34. Kishi K, Homma S, Kurosaki A, Kohno T, Motoi N, Yoshimura K. Clinical features and high-resolution CT findings of pulmonary cryptococcosis in non-AIDS patients. Respir. Med. 100(5), 807-812 (2006).
35. Lin X, Heitman J. The biology of the Cryptococcus neoformans species complex. Annu. Rev. Microbiol. 60, 69-105 (2006).
36. Dromer F, Ronin O, Dupont B. Isolation of Cryptococcus neoformans var. gattii from an Asian patient in France: Evidence for dormant infection in healthy subjects. J. Med. Vet. Mycol. 30(5), 395-397 (1992).
37. Garcia-Hermoso D, Janbon G, Dromer F. Epidemiological evidence for dormant Cryptococcus neoformans infection. J. Clin. Microbiol. 37(10), 3204-3209 (1999).
38. Goldman D, Song X, Kitai R, Casadevall A, Zhao ML, Lee SC. Cryptococcus neoformans induces macrophage inflammatory protein 1a (MIP-1a) and MIP-1b in human microglia: Role of specific antibody and soluble capsular polysaccharide. Infect. Immun. 69(3), 1808-1815 (2001).
39. Ngamskulrungroj P, Chang Y, Sionov E, Kwon-Chung KJ. The primary target organ of Cryptococcus gattii is different from that of Cryptococcus neoformans in a murine model. mBio 3(3), e00103-12 (2012) .
40. Velagapudi R, Hsueh YP, Geunes-Boyer S, Wright JR, Heitman J. Spores as infectious propagules of Cryptococcus neoformans. Infect. Immun. 77(10), 4345-4355 (2009).
41. Giles SS, Dagenais TR, Botts MR, Keller NP, Hull CM. Elucidating the pathogenesis of spores from the human fungal pathogen Cryptococcus neoformans. Infect. Immun. 77(8), 3491-3500 (2009).
42. Levitz SM, Selsted ME, Ganz T, Lehrer RI, Diamond RD. In vitro killing of spores and hyphae of Aspergillus fumigatus and Rhizopus oryzae by rabbit neutrophil cationic peptides and bronchoalveolar macrophages. J. Infect. Dis. 154(3), 483-489 (1986).
43. Botts MR, Giles SS, Gates MA, Kozel TR, Hull CM. Isolation and characterization of Cryptococcus neoformans spores reveal a critical role for capsule biosynthesis genes in spore biogenesis. Eukaryot. Cell 8(4), 595-605 (2009).
44. Ganendren R, Carter E, Sorrell T, Widmer F, Wright L. Phospholipase B activity enhances adhesion of Cryptococcus neoformans to a human lung epithelial cell line. Microbes Infect. 8(4), 1006-1015 (2006).
45. Geunes-Boyer S, Beers MF, Perfect JR, Heitman J, Wright Jr. Surfactant protein D facilitates Cryptococcus neoformans infection. Infect. Immun. 80(7), 2444-2453 (2012).
46. Gordon SB, Read RC. Macrophage defences against respiratory tract infections. Br. Med. Bull. 61, 45-61 (2002).
47. Goldman DL, Lee SC, Mednick AJ, Montella L, Casadevall A. Persistent Cryptococcus neoformans pulmonary infection in the rat is associated with intracellular parasitism, decreased inducible nitric oxide synthase expression, and altered antibody responsiveness to cryptococcal polysaccharide. Infect. Immun. 68(2), 832-838 (2000).
48. Shao X, Mednick A, Alvarez M, van Rooijen N, Casadevall A, Goldman DL. An innate immune system cell is a major determinant of species-related susceptibility differences to fungal pneumonia. J. Immunol. 175(5), 3244-3251 (2005).
49. Kechichian TB, Shea J, Del Poeta M. Depletion of alveolar macrophages decreases the dissemination of a glucosylceramidedeficient mutant of Cryptococcus neoformans in immunodeficient mice. Infect. Immun. 75(10), 4792-4798 (2007).
50. Meyohas MC, Roux P, Bollens D et al. Pulmonary cryptococcosis: Localized and disseminated infections in 27 patients with AIDS. Clin. Infect. Dis. 21(3), 628-633 (1995).
51. Zaragoza O, Rodrigues ML, De Jesus M, Frases S, Dadachova E, Casadevall A. The capsule of the fungal pathogen Cryptococcus neoformans. Adv. Appl. Microbiol. 68, 133-216 (2009).
52. Syme RM, Bruno TF, Kozel TR, Mody CH. The capsule of Cryptococcus neoformans reduces T-lymphocyte proliferation by reducing phagocytosis, which can be restored with anticapsular antibody. Infect. Immun. 67(9), 4620-4627 (1999).
53. Vecchiarelli A, Dottorini M, Pietrella D et al. Role of human alveolar macrophages as antigen-presenting cells in Cryptococcus neoformans infection. Am. J. Respir. Cell. Mol. Biol. 11(2), 130-137 (1994).
54. Xie S, Sao R, Braun A, Bottone EJ. Difference in Cryptococcus neoformans cellular and capsule size in sequential pulmonary and meningeal infection: A postmortem study. Diagn. Microbiol. Infect. Dis. 73(1), 49-52 (2012).
55. Stano P, Williams V, Villani M et al. App1: An antiphagocytic protein that binds to complement receptors 3 and 2. J. Immunol. 182(1), 84-91 (2009).
56. Chun CD, Brown JC, Madhani HD. A major role for capsule-independent phagocytosisinhibitory mechanisms in mammalian infection by Cryptococcus neoformans. Cell Host Microbe 9(3), 243-251 (2011
57. Garcia-Rodas R, Zaragoza O. Catch me if you can: Phagocytosis and killing avoidance by Cryptococcus neoformans. FEMS Immunol. Med. Microbiol. 64(2), 147-161 (2012).
58. Nielsen K, Cox GM, Litvintseva AP et al. Cryptococcus neoformans a strains preferentially disseminate to the central nervous system during coinfection. Infect. Immun. 73(8), 4922-4933 (2005).
59. Zaragoza O, Garcia-Rodas R, Nosanchuk JD, Cuenca-Estrella M, Rodriguez-Tudela JL, Casadevall A. Fungal cell gigantism during mammalian infection. Plos Pathog. 6(6), e1000945 (2010).
60. Okagaki LH, Strain AK, Nielsen JN et al. Cryptococcal cell morphology affects host cell interactions and pathogenicity. Plos Pathog. 6(6), e1000953 (2010).
61. Okagaki LH, Nielsen K. Titan cells confer protection from phagocytosis in Cryptococcus neoformans infections. Eukaryot. Cell 11(6), 820-826 (2012).
62. Casadevall A, Freundlich LF, Marsh L, Scharff MD. Extensive allelic variation in Cryptococcus neoformans. J. Clin. Microbiol. 30(5), 1080-1084 (1992).
63. Dromer F, Salamero J, Contrepois A, Carbon C, Yeni P. Production, characterization, and antibody specificity of a mouse monoclonal antibody reactive with Cryptococcus neoformans capsular polysaccharide. Infect. Immun. 55(3), 742-748 (1987).
64. Kozel TR, Pfrommer GS, Guerlain AS, Highison BA, Highison GJ. Strain variation in phagocytosis of Cryptococcus neoformans: Dissociation of susceptibility to phagocytosis from activation and binding of opsonic fragments of C3. Infect. Immun. 56(11), 2794-2800 (1988).
65. Eckert TF, Kozel TR. Production and characterization of monoclonal antibodies specific for Cryptococcus neoformans capsular polysaccharide. Infect. Immun. 55(8), 1895-1899 (1987).
66. Pirofski L, Lui R, DeShaw M, Kressel AB, Zhong Z. Analysis of human monoclonal antibodies elicited by vaccination with a Cryptococcus neoformans glucuronoxylomannan capsular polysaccharide vaccine. Infect. Immun. 63(8), 3005-3014 (1995).
67. Todaro-Luck F, Reiss E, Cherniak R, Kaufman L. Characterization of Cryptococcus neoformans capsular glucuronoxylomannan polysaccharide with monoclonal antibodies. Infect. Immun. 57(12), 3882-3887 (1989).
68. Kozel TR, Pfrommer GS. Activation of the complement system by Cryptococcus neoformans leads to binding of iC3b to the yeast. Infect. Immun. 52(1), 1-5 (1986).
69. Kozel TR, Wilson MA, Pfrommer GS, Schlageter AM. Activation and binding of opsonic fragments of C3 on encapsulated Cryptococcus neoformans by using an alternative complement pathway reconstituted from six isolated proteins. Infect. Immun. 57(7), 1922-1927 (1989).
70. Ma H, Croudace JE, Lammas DA, May RC. Expulsion of live pathogenic yeast by macrophages. Curr. Biol. 16(21), 2156-2160 (2006).
71. Ma H, Hagen F, Stekel DJ et al. The fatal fungal outbreak on Vancouver Island is characterized by enhanced intracellular parasitism driven by mitochondrial regulation. Proc. Natl Acad. Sci. USA 106(31), 12980-12985 (2009).
72. Alvarez M, Casadevall A. Phagosome extrusion and host-cell survival after Cryptococcus neoformans phagocytosis by macrophages. Curr. Biol. 16(21), 2161-2165 (2006).
73. Johnston SA, May RC. The human fungal pathogen Cryptococcus neoformans escapes macrophages by a phagosome emptying mechanism that is inhibited by Arp2/3 complex-mediated actin polymerisation. Plos Pathog. 6(8), e1001041 (2010).
74. Ma H, Croudace JE, Lammas DA, May RC. Direct cell-to-cell spread of a pathogenic yeast. BMC Immunol. 8, 15 (2007).
75. Alvarez M, Casadevall A. Cell-to-cell spread and massive vacuole formation after Cryptococcus neoformans infection of murine macrophages. BMC Immunol. 8, 16 (2007).
76. Naslund PK, Miller WC, Granger DL. Cryptococcus neoformans fails to induce nitric oxide synthase in primed murine macrophage-like cells. Infect. Immun. 63(4), 1298-1304 (1995).
77. Zaragoza O, Chrisman CJ, Castelli MV et al. Capsule enlargement in Cryptococcus neoformans confers resistance to oxidative stress suggesting a mechanism for intracellular survival. Cell. Microbiol. 10(10), 2043-2057 (2008).
78. Lee SC, Kress Y, Zhao ML, Dickson DW, Casadevall A. Cryptococcus neoformans survive and replicate in human microglia. Lab. Invest. 73(6), 871-879 (1995).
79. Tucker SC, Casadevall A. Replication of Cryptococcus neoformans in macrophages is accompanied by phagosomal permeabilization and accumulation of vesicles containing polysaccharide in the cytoplasm. Proc. Natl Acad. Sci. USA 99(5), 3165-3170 (2002).
80. Casadevall A, Rosas AL, Nosanchuk JD. Melanin and virulence in Cryptococcus neoformans. Curr. Opin. Microbiol. 3(4), 354-358 (2000).
81. Williamson PR. Laccase and melanin in the pathogenesis of Cryptococcus neoformans. Front. Biosci. 2, E99-E107 (1997).
82. Emery HS, Shelburne CP, Bowman JP, Fallon PG, Schulz CA, Jacobson ES. Genetic study of oxygen resistance and melanization in Cryptococcus neoformans. Infect. Immun. 62(12), 5694-5697 (1994).
83. van Duin D, Casadevall A, Nosanchuk JD. Melanization of Cryptococcus neoformans and Histoplasma capsulatum reduces their susceptibilities to amphotericin B and caspofungin. Antimicrob. Agents Chemother. 46(11), 3394-3400 (2002).
84. Messer SA, Moet GJ, Kirby JT, Jones RN. Activity of contemporary antifungal agents, including the novel echinocandin anidulafungin, tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: Report from the SENTRY Antimicrobial Surveillance Program (2006 to 2007). J. Clin. Microbiol. 47(6), 1942-1946 (2009).
85. Hu G, Wang J, Choi J et al. Variation in chromosome copy number influences the virulence of Cryptococcus neoformans and occurs in isolates from AIDS patients. BMC Genomics 12, 526 (2011).
86. Chang YC, Bien CM, Lee H, Espenshade PJ, Kwon-Chung K. Sre1p, a regulator of oxygen sensing and sterol homeostasis, is required for virulence in Cryptococcus neoformans. Mol. Microbiol. 64(3), 614-629 (2007).
87. Price MS, Betancourt-Quiroz M, Price JL et al. Cryptococcus neoformans requires a functional glycolytic pathway for disease but not persistence in the host. MBio 2(3), e00103-11 (2011).
88. Fan W, Kraus PR, Boily MJ, Heitman J. Cryptococcus neoformans gene expression during murine macrophage infection. Eukaryot. Cell 4(8), 1420-1433 (2005).
89. Hu G, Cheng PY, Sham A, Perfect JR, Kronstad JW. Metabolic adaptation in Cryptococcus neoformans during early murine pulmonary infection. Mol. Microbiol. 69(6), 1456-1475 (2008).
90. Kretschmer M, Wang J, Kronstad JW. Peroxisomal and mitochondrial boxidation influence the virulence of the pathogenic fungus Cryptococcus neoformans. Eukaryot. Cell 11(8), 1042-1054 (2012).
91. Williamson PR. Biochemical and molecular characterization of the diphenol oxidase of Cryptococcus neoformans: Identification as a laccase. J. Bacteriol. 176(3), 656-664 (1994).
92. Chun CD, Madhani HD. Ctr2 links copper homeostasis to polysaccharide capsule formation and phagocytosis inhibition in the human fungal pathogen Cryptococcus neoformans. Plos One 5(9), e12503 (2010).
93. Waterman SR, Hacham M, Hu G et al. Role of a CUF1/CTR4 copper regulatory axis in the virulence of Cryptococcus neoformans. J. Clin. Invest. 117(3), 794-802 (2007).
94. Silva FD, Rossi DC, Martinez LR et al. Effects of microplusin, a copper-chelating antimicrobial peptide, against Cryptococcus neoformans. FEMS Microbiol. Lett. 324(1), 64-72 (2011).
95. Schaible UE, Kaufmann SH. Iron and microbial infection. Nat. Rev. Microbiol. 2(12), 946-953 (2004).
96. Philpott CC. Iron uptake in fungi: A system for every source. Biochim. Biophys. Acta 1763(7), 636-645 (2006).
97. Jung WH, Hu G, Kuo W, Kronstad JW. Role of ferroxidases in iron uptake and virulence of Cryptococcus neoformans. Eukaryot. Cell 8(10), 1511-1520 (2009).
98. Jung WH, Kronstad JW. Iron and fungal pathogenesis: A case study with Cryptococcus neoformans. Cell. Microbiol. 10(2), 277-284 (2008).
99. Qin QM, Luo J, Lin X et al. Functional analysis of host factors that mediate the intracellular lifestyle of Cryptococcus neoformans. Plos Pathog. 7(6), e1002078 (2011).
100. Nicola AM, Albuquerque P, Martinez LR et al. Macrophage autophagy in immunity to Cryptococcus neoformans and Candida albicans. Infect. Immun. 80(9), 3065-3076 (2012).
101. Zhang Y, Wang F, Tompkins KC et al. Robust Th1 and Th17 immunity supports pulmonary clearance but cannot prevent systemic dissemination of highly virulent Cryptococcus neoformans H99. Am. J. Pathol. 175(6), 2489-2500 (2009).
102. Osterholzer JJ, Surana R, Milam JE et al. Cryptococcal urease promotes the accumulation of immature dendritic cells and a non-protective T2 immune response within the lung. Am. J. Pathol. 174(3), 932-943 (2009).
103. Vecchiarelli A, Monari C. Capsular material of Cryptococcus neoformans: Virulence and much more. Mycopathologia doi:10.1007/s11046-011-9513-8 (2012) (Epub ahead of print).
104. Siddiqui AA, Shattock RJ, Harrison TS. Role of capsule and interleukin-6 in long-term immune control of Cryptococcus neoformans infection by specifically activated human peripheral blood mononuclear cells. Infect. Immun. 74(9), 5302-5310 (2006).
105. Valdez PA, Vithayathil PJ, Janelsins BM, Shaffer AL, Williamson PR, Datta SK. Prostaglandin E2 suppresses antifungal immunity by inhibiting interferon regulatory factor 4 function and interleukin-17 expression in T cells. Immunity 36(4), 668-679 (2012).
106. Pukkila-Worley R, Alspaugh JA. Cyclic AMP signaling in Cryptococcus neoformans. FEMS Yeast Res. 4(4-5), 361-367 (2004).
107. Salas SD, Bennett JE, Kwon-Chung K, Perfect JR, Williamson PR. Effect of the laccase gene CNLAC1, on virulence of Cryptococcus neoformans. J. Exp. Med. 184(2), 377-386 (1996).
108. Wright LC, Payne J, Santangelo RT et al. Cryptococcal phospholipases: A novel lysophospholipase discovered in the pathogenic fungus Cryptococcus gattii. Biochem. J. 384, 377-384 (2004).
109. Ghannoum MA. Potential role of phospholipases in virulence and fungal pathogenesis. Clin. Microbiol. Rev. 13(1), 122-143, table of contents (2000).
110. Santangelo R, Zoellner H, Sorrell T et al. Role of extracellular phospholipases and mononuclear phagocytes in dissemination of cryptococcosis in a murine model. Infect. Immun. 72(4), 2229-2239 (2004).
111. Steenbergen JN, Casadevall A. The origin and maintenance of virulence for the human pathogenic fungus Cryptococcus neoformans. Microbes Infect. 5(7), 667-675 (2003).
112. Wright LC, Santangelo RM, Ganendren R, Payne J, Djordjevic JT, Sorrell TC. Cryptococcal lipid metabolism: Phospholipase B1 is implicated in transcellular metabolism of macrophagederived lipids. Eukaryot. Cell 6(1), 37-47 (2007).
113. Noverr MC, Cox GM, Perfect JR, Huffnagle GB. Role of PLB1 in pulmonary inflammation and cryptococcal eicosanoid production. Infect. Immun. 71(3), 1538-1547 (2003).
114. Djordjevic JT. Role of phospholipases in fungal fitness, pathogenicity, and drug development - lessons from Cryptococcus neoformans. Front. Microbiol. 1, 125 (2010).
115. Chen SC, Muller M, Zhou JZ, Wright LC, Sorrell TC. Phospholipase activity in Cryptococcus neoformans: A new virulence factor? J. Infect. Dis. 175(2), 414-420 (1997).
116. Cox GM, McDade HC, Chen SC et al. Extracellular phospholipase activity is a virulence factor for Cryptococcus neoformans. Mol. Microbiol. 39(1), 166-175 (2001).
117. Maruvada R, Zhu L, Pearce D et al. Cryptococcus neoformans phospholipase B1 activates host cell Rac1 for traversal across the blood-brain barrier. Cell. Microbiol. 14(10), 1544-1553 (2012
118. Chen LC, Blank ES, Casadevall A. Extracellular proteinase activity of Cryptococcus neoformans. Clin. Diagn. Lab. Immunol. 3(5), 570-574 (1996).
119. Cox GM, Mukherjee J, Cole GT, Casadevall A, Perfect Jr. Urease as a virulence factor in experimental cryptococcosis. Infect. Immun. 68(2), 443-448 (2000).
120. Olszewski MA, Noverr MC, Chen GH et al. Urease expression by Cryptococcus neoformans promotes microvascular sequestration, thereby enhancing central nervous system invasion. Am. J. Pathol. 164(5), 1761-1771 (2004).
121. Charlier C, Chretien F, Baudrimont M, Mordelet E, Lortholary O, Dromer F. Capsule structure changes associated with Cryptococcus neoformans crossing of the blood-brain barrier. Am. J. Pathol. 166(2), 421-432 (2005).
122. Shi M, Li SS, Zheng C et al. Real-time imaging of trapping and urease-dependent transmigration of Cryptococcus neoformans in mouse brain. J. Clin. Invest. 120(5), 1683-1693 (2010
123. Correale J, Villa A. Cellular elements of the blood-brain barrier. Neurochem. Res. 34(12), 2067-2077 (2009).
124. Weksler BB, Subileau EA, Perriere N et al. Blood-brain barrier-specific properties of a human adult brain endothelial cell line. FASEB J. 19(13), 1872-1874 (2005).
125. Brown RC, Morris AP, O'Neil RG. Tight junction protein expression and barrier properties of immortalized mouse brain microvessel endothelial cells. Brain Res. 1130(1), 17-30 (2007).
126. Charlier C, Chretien F, Lortholary O, Dromer F. [Early capsule structure changes associated with Cryptococcus neoformans crossing of the blood-brain barrier.] Med. Sci. (Paris) 21(8-9), 685-687 (2005).
127. Kim KS. Mechanisms of microbial traversal of the blood-brain barrier. Nat. Rev. Microbiol. 6(8), 625-634 (2008).
128. Charlier C, Nielsen K, Daou S, Brigitte M, Chretien F, Dromer F. Evidence of a role for monocytes in dissemination and brain invasion by Cryptococcus neoformans. Infect. Immun. 77(1), 120-127 (2009
129. Feldmesser M, Kress Y, Casadevall A. Dynamic changes in the morphology of Cryptococcus neoformans during murine pulmonary infection. Microbiology 147, 2355-2365 (2001).
130. Drevets DA, Leenen PJ. Leukocyte-facilitated entry of intracellular pathogens into the central nervous system. Microbes Infect. 2(13), 1609-1618 (2000).
131. Drevets DA, Leenen PJ, Greenfield RA. Invasion of the central nervous system by intracellular bacteria. Clin. Microbiol. Rev. 17(2), 323-347 (2004).
132. Drevets DA. Dissemination of Listeria monocytogenes by infected phagocytes. Infect. Immun. 67(7), 3512-3517 (1999).
133. Kanmogne GD, Schall K, Leibhart J, Knipe B, Gendelman HE, Persidsky Y. HIV-1 gp120 compromises blood-brain barrier integrity and enhances monocyte migration across blood-brain barrier: Implication for viral neuropathogenesis. J. Cereb. Blood Flow Metab. 27(1), 123-134 (2007).
134. Lachenmaier SM, Deli MA, Meissner M, Liesenfeld O. Intracellular transport of Toxoplasma gondii through the blood-brain barrier. J. Neuroimmunol. 232(1-2), 119-130 (2011).
135. Montoya JG, Liesenfeld O. Toxoplasmosis. Lancet 363(9425), 1965-1976 (2004).
136. Chang YC, Wang Z, Flax LA et al. Glycosaminoglycan binding facilitates entry of a bacterial pathogen into central nervous systems. Plos Pathog. 7(6), e1002082 (2011).
137. Jain N, Wickes BL, Keller SM et al. Molecular epidemiology of clinical Cryptococcus neoformans strains from India. J. Clin. Microbiol. 43(11), 5733-5742 (2005).
138. Vu K, Weksler B, Romero I, Couraud PO, Gelli A. Immortalized human brain endothelial cell line HCMEC/D3 as a model of the blood-brain barrier facilitates in vitro studies of central nervous system infection by Cryptococcus neoformans. Eukaryot. Cell 8(11), 1803-1807 (2009).
139. Chen SH, Stins MF, Huang SH et al. Cryptococcus neoformans induces alterations in the cytoskeleton of human brain microvascular endothelial cells. J. Med. Microbiol. 52, 961-970 (2003).
140. Chang YC, Wright LC, Tscharke RL, Sorrell TC, Wilson CF, Kwon-Chung K. Regulatory roles for the homeodomain and C2H2 zinc finger regions of Cryptococcus neoformans Ste12alphap. Mol. Microbiol. 53(5), 1385-1396 (2004).
141. Chang YC, Stins MF, McCaffery MJ et al. Cryptococcal yeast cells invade the central nervous system via transcellular penetration of the blood-brain barrier. Infect. Immun. 72(9), 4985-4995 (2004
142. Jong A, Wu CH, Shackleford GM et al. Involvement of human CD44 during Cryptococcus neoformans infection of brain microvascular endothelial cells. Cell. Microbiol. 10(6), 1313-1326 (2008).
143. Huang SH, Long M, Wu CH et al. Invasion of Cryptococcus neoformans into human brain microvascular endothelial cells is mediated through the lipid rafts-endocytic pathway via the dual specificity tyrosine phosphorylation- regulated kinase 3 (DYRK3). J. Biol. Chem. 286(40), 34761-34769 (2011).
144. Goodison S, Urquidi V, Tarin D. CD44 cell adhesion molecules. Mol. Pathol. 52(4), 189-196 (1999).
145. Ponta H, Sherman L, Herrlich PA. CD44: From adhesion molecules to signalling regulators. Nat. Rev. Mol. Cell. Biol. 4(1), 33-45 (2003).
146. Ibrahim AS, Filler SG, Alcouloumre MS, Kozel TR, Edwards JE Jr, Ghannoum MA. Adherence to and damage of endothelial cells by Cryptococcus neoformans in vitro: Role of the capsule. Infect. Immun. 63(11), 4368-4374 (1995).
147. Fries BC, Taborda CP, Serfass E, Casadevall A. Phenotypic switching of Cryptococcus neoformans occurs in vivo and influences the outcome of infection. J. Clin. Invest. 108(11), 1639-1648 (2001).
148. Guerrero A, Jain N, Goldman DL, Fries BC. Phenotypic switching in Cryptococcus neoformans. Microbiology 152, 3-9 (2006).
149. Jain N, Guerrero A, Fries BC. Phenotypic switching and its implications for the pathogenesis of Cryptococcus neoformans. FEMS Yeast Res. 6(4), 480-488 (2006).
150. Sabiiti W, May RC. Capsule independent uptake of the fungal pathogen Cryptococcus neoformans into brain microvascular endothelial cells. Plos One 7(4), e35455 (2012).
151. Stie J, Bruni G, Fox D. Surface-associated plasminogen binding of Cryptococcus neoformans promotes extracellular matrix invasion. Plos One 4(6), e5780 (2009).
152. Boven LA, Middel J, Verhoef J, De Groot CJ, Nottet HS. Monocyte infiltration is highly associated with loss of the tight junction protein zonula occludens in HIV-1-associated dementia. Neuropathol. Appl. Neurobiol. 26(4), 356-360 (2000).
153. Nottet HS, Bar DR, van Hassel H, Verhoef J, Boven LA. Cellular aspects of HIV-1 infection of macrophages leading to neuronal dysfunction in in vitro models for HIV-1 encephalitis. J. Leukoc. Biol. 62(1), 107-116 (1997).
154. Kim TA, Avraham HK, Koh YH, Jiang S, Park IW, Avraham S. HIV-1 Tat-mediated apoptosis in human brain microvascular endothelial cells. J. Immunol. 170(5), 2629-2637 (2003).
155. Avraham HK, Jiang S, Lee TH, Prakash O, Avraham S. HIV-1 Tat-mediated effects on focal adhesion assembly and permeability in brain microvascular endothelial cells. J. Immunol. 173(10), 6228-6233 (2004).
156. Jong AY, Wu CH, Jiang S, Feng L, Chen HM, Huang SH. HIV-1 gp41 ectodomain enhances Cryptococcus neoformans binding to HBMEC. Biochem. Biophys. Res. Commun. 356(4), 899-905 (2007).
157. Boulware DR, Bonham SC, Meya DB et al. Paucity of initial cerebrospinal fluid inflammation in cryptococcal meningitis is associated with subsequent immune reconstitution inflammatory syndrome. J. Infect. Dis. 202(6), 962-970 (2010).
158. Bicanic T, Harrison TS. Cryptococcal meningitis. Br. Med. Bull. 72, 99-118 (2005).
159. Mwaba P, Mwansa J, Chintu C et al. Clinical presentation, natural history, and cumulative death rates of 230 adults with primary cryptococcal meningitis in Zambian AIDS patients treated under local conditions. Postgrad. Med. J. 77(914), 769-773 (2001).
160. Nussbaum JC, Jackson A, Namarika D et al. Combination flucytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: A randomized trial in Malawi. Clin. Infect. Dis. 50(3), 338-344 (2010).
161. Lee SC, Dickson DW, Casadevall A. Pathology of cryptococcal meningoencephalitis: Analysis of 27 patients with pathogenetic implications. Hum. Pathol. 27(8), 839-847 (1996).
162. Loyse A, Wainwright H, Jarvis JN et al. Histopathology of the arachnoid granulations and brain in HIV-associated cryptococcal meningitis:Correlation with cerebrospinal fluid pressure. AIDS 24(3), 405-410 (2010).
163. Bicanic T, Brouwer AE, Meintjes G et al. Relationship of cerebrospinal fluid pressure, fungal burden and outcome in patients with cryptococcal meningitis undergoing serial lumbar punctures. AIDS 23(6), 701-706 (2009).
164. Mora DJ, da Cunha Colombo ER, Ferreira-Paim K, Andrade-Silva LE, Nascentes GA, Silva-Vergara ML. Clinical, epidemiological and outcome features of patients with cryptococcosis in Uberaba, Minas Gerais, Brazil. Mycopathologia 173(5-6), 321-327 (2012).
165. Steele KT, Thakur R, Nthobatsang R, Steenhoff AP, Bisson GP. In-hospital mortality of HIV-infected cryptococcal meningitis patients with C. gattii and C. neoformans infection in Gaborone, Botswana. Med. Mycol. 48(8), 1112-1115 (2010).
166. Perfect JR, Dismukes WE, Dromer F et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 50(3), 291-322 (2010).
167. Sabiiti W, May RC, Pursall ER. Experimental models of cryptococcosis. Int. J. Microbiol. 2012, 626745 (2012).
168. Del Poeta M, Casadevall A. Ten challenges on Cryptococcus and cryptococcosis. Mycopathologia 173(5-6), 303-310 (2012).
169. Sorrell TC, Brownlee AG, Ruma P, Malik R, Pfeiffer TJ, Ellis DH. Natural environmental sources of Cryptococcus neoformans var. gattii. J. Clin. Microbiol. 34(5), 1261-1263 (1996).
170. Chowdhary A, Rhandhawa HS, Prakash A, Meis JF. Environmental prevalence of Cryptococcus neoformans and Cryptococcus gattii in India: An update. Crit. Rev. Microbiol. 38(1), 1-16 (2012).
171. Waikedre J, Vitturo CI, Molina A et al. Antifungal activity of the essential oils of Callitris neocaledonica and C. sulcata heartwood (Cupressaceae). Chem. Biodivers. 9(3), 644-653 (2012).
172. Perfect JR, Lang SD, Durack DT. Chronic cryptococcal meningitis: A new experimental model in rabbits. Am. J. Pathol. 101(1), 177-194 (1980).
173. Rude TH, Toffaletti DL, Cox GM, Perfect Jr. Relationship of the glyoxylate pathway to the pathogenesis of Cryptococcus neoformans. Infect. Immun. 70(10), 5684-5694 (2002).
174. Lee A, Toffaletti DL, Tenor J et al. Survival defects of Cryptococcus neoformans mutants exposed to human cerebrospinal fluid result in attenuated virulence in an experimental model of meningitis. Infect. Immun. 78(10), 4213-4225 (2010).
175. Lee YC, Wang JT, Sun HY, Chen YC. Comparisons of clinical features and mortality of cryptococcal meningitis between patients with and without human immunodeficiency virus infection. J. Microbiol. Immunol. Infect. 44(5), 338-345 (2011).
176. Jung WH, Sham A, Lian T, Singh A, Kosman DJ, Kronstad JW. Iron source preference and regulation of iron uptake in Cryptococcus neoformans. Plos Pathog. 4(2), e45 (2008).
177. Jong AY, Stins MF, Huang SH, Chen SH, Kim KS. Traversal of Candida albicans across human blood-brain barrier in vitro. Infect. Immun. 69(7), 4536-4544 (2001).